StemCell Therapy

Following the leaves, a given rhizome will produce one or more flowering stalks. These stalks (also roughened) are without leaves themselves: such a stalk is called a scape. (Another good example of a scape would be the stem of a daffodil.). Each scape will bear a single flower, all the way at the top. A football-shaped, green bud eventually will open up, allowing the flowers 15 or so exquisitely pink (sometimes white) tepals to spread open. The center of the flower bears a lot of stamens, often more than 100, and several pistils, with each pistil embedded in a flattened receptacle.

At maturity, the tepals have all fallen away, and the receptacle swells a bit into a conical shape, with very hard, spherical seeds embedded in its tissue. These seeds are amazing for their longevity, easily sprouting after 100 years of dormancy. Some reports indicate that they may still be good after several centuries.

The entire plant, in addition to the rhizomes, has been used since antiquity in central and eastern Asia, where it is native, in various ways. But it is the extraordinary blossoms that make this species so special: a plant that can resurrect itself from quiet mud into something resplendent and almost sacred.

By the way, the seeds will sprout if scarified, and sometimes the rhizomes are available for planting. Be aware that, if happy enough, this plant can be invasive.

Visit link:
Mystery Plant: Beautiful, magical and edible, this aquatic bloom has many uses - The Daily Progress

Shares of Aclaris Therapeutics Inc. ACRS, +192.35% skyrocketed more than 200% toward a 2 1/2-year high, on massive volume, in midday trading Tuesday, after the biopharmaceutical company announced "positive" data from a Phase 2a trial of its rheumatoid arthritis treatment. The stock shot up 211.1%, putting it on track for the highest close since July 2018, to pace all gainers on major U.S. exchanges. Trading volume soared to 79.7 million shares, compared with the full-day average of about 859,000 shares. The company said the Phase 2a multicenter trial was randomized, patient-blind, sponsor-unblinded and placebo-controlled, and the primary endpoint was safety and tolerability of ATI-450, an investigational oral MK2 inhibitor. In the trial, the company said ATI-450 as generally well tolerated, showed no serious adverse events and demonstrated durable clinical activity. Aclaris Chief Medical Officer David Gordon said he believes the data supports the hypothesis that MK2 inhibition is an important novel target for treating immuno-inflammatory diseases, and he looks forward to progressing ATI-450 to Phase 2b. The stock has soared more than four-fold (up 305.5%) over the past three months, while the iShares Nasdaq Biotechnology ETF IBB, +1.75% has rallied 19.4% and the S&P 500 SPX, +0.80% has gained 10.6%.

See the original post here:
Aclaris Therapeutics stock more than triples after 'positive' data on arthritis treatment trial - MarketWatch

DEAR DR. ROACH: I would like to know how to treat arthritis. I have been using Voltaren per my doctors orders, but it does not seem to be helping much. I have also been taking ibuprofen, but I am afraid of stomach bleeding. The arthritis is in my wrists and thumb. I can hardly open a doorknob or lift any small objects. Does turmeric help?

I would appreciate any advice you can give me. It is hard to do any cooking or housework using my hands. They ache and throb all day. M.V.

ANSWER: There are several different types of arthritis of the hand, and it sounds as though your doctor has made the diagnosis of osteoarthritis, which is the most common type. Rheumatoid arthritis and psoriatic arthritis are inflammatory varieties that require very different therapies. Blood testing and X-rays help separate the different types of arthritis from one another if your history and physical exam indicate the need.

If you have osteoarthritis, oral anti-inflammatory medicines like Voltaren or ibuprofen (but NEVER both taking two different NSAIDs orally adds only toxicity, not effectiveness) are common and often effective treatments. Voltaren is also available as a gel, and its OK to use both Voltaren gel and a different oral NSAID such as ibuprofen. The gel is poorly absorbed into the body and is very unlikely to have systemic side effects.

However, remember that exercise improves pain and function. One set of exercises specifically for hand arthritis from the Mayo Clinic can be found at tinyurl.com/mayo-hand.

You asked about turmeric. There are studies showing benefit for turmeric and it has little toxicity, so I think it is worth a try. Similarly, Boswellia supplements have shown benefit in some people with osteoarthritis.

DEAR DR. ROACH: I tested positive for COVID-19 about six weeks ago. I had very mild symptoms for about 24 hours. I lost my sense of taste and smell. My senses are slowly returning, but now I constantly have a strange taste in my mouth. I cant tell if its a metallic taste or not. Eating, drinking, chewing gum, brushing, etc., make it go away for 10 minutes. Is this COVID-related or something else? Will it go away? -- M.R.

ANSWER: While I cant answer with certainty, many people with COVID-19 have disturbances in taste and smell that take weeks or months to resolve. Based on my experience with these patients, I would guess your disturbance is most likely COVID-19 related, and is likely to go away in time.

Dr. Roach regrets that he is unable to answer individual letters, but will incorporate them in the column whenever possible. Readers may email questions to ToYourGoodHealth@med.cornell.edu or send mail to 628 Virginia Dr., Orlando, FL 32803.

Read more here:
Arthritis treatment needed for pain in hands - Northeast Mississippi Daily Journal

Machine learning was shown to identify patients with rheumatoid arthritis (RA) who present an increased chance of achieving clinical response with sarilumab, with those selected also showing an inferior response to adalimumab, according to an abstract presented at ACR Convergence, the annual meeting of the American College of Rheumatology (ACR).

In prior phase 3 trials comparing the interleukin 6 receptor (IL-6R) inhibitor sarilumab with placebo and the tumor necrosis factor (TNF-) inhibitor adalimumab, sarilumab appeared to provide superior efficacy for patients with moderate to severe RA. Although promising, the researchers of the abstract highlight that treatment of RA requires a more individualized approach to maximize efficacy and minimize risk of adverse events.

The characteristics of patients who are most likely to benefit from sarilumab treatment remain poorly understood, noted researchers.

Seeking to better identify the patients with RA who may best benefit from sarilumab treatment, the researchers applied machine learning to select from a predefined set of patient characteristics, which they hypothesized may help delineate the patients who could benefit most from either antiIL-6R or antiTNF- treatment.

Following their extraction of data from the sarilumab clinical development program, the researchers utilized a decision tree classification approach to build predictive models on ACR response criteria at week 24 in patients from the phase 3 MOBILITY trial, focusing on the 200-mg dose of sarilumab. They incorporated the Generalized, Unbiased, Interaction Detection and Estimation (GUIDE) algorithm, including 17 categorical and 25 continuous baseline variables as candidate predictors. These included protein biomarkers, disease activity scoring, and demographic data, added the researchers.

Endpoints used were ACR20, ACR50, and ACR70 at week 24, with the resulting rule validated through application on independent data sets from the following trials:

Assessing the end points used, it was found that the most successful GUIDE model was trained against the ACR20 response. From the 42 candidate predictor variables, the combined presence of anticitrullinated protein antibodies (ACPA) and C-reactive protein >12.3 mg/L was identified as a predictor of better treatment outcomes with sarilumab, with those patients identified as rule-positive.

These rule-positive patients, which ranged from 34% to 51% in the sarilumab groups across the 4 trials, were shown to have more severe disease and poorer prognostic factors at baseline. They also exhibited better outcomes than rule-negative patients for most end points assessed, except for patients with inadequate response to TNF inhibitors.

Notably, rule-positive patients had a better response to sarilumab but an inferior response to adalimumab, except for patients of the HAQ-Disability Index minimal clinically important difference end point.

If verified in prospective studies, this rule could facilitate treatment decision-making for patients with RA, concluded the researchers.

Reference

Rehberg M, Giegerich C, Praestgaard A, et al. Identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Presented at: ACR Convergence 2020; November 5-9, 2020. Accessed January 15, 2021. 021. Abstract 2006. https://acrabstracts.org/abstract/identification-of-a-rule-to-predict-response-to-sarilumab-in-patients-with-rheumatoid-arthritis-using-machine-learning-and-clinical-trial-data/

The rest is here:
Machine Learning Shown to Identify Patient Response to Sarilumab in Rheumatoid Arthritis - AJMC.com Managed Markets Network

This article was originally published here

J Rheumatol. 2021 Jan 15:jrheum.201226. doi: 10.3899/jrheum.201226. Online ahead of print.

ABSTRACT

OBJECTIVE: Both erectile dysfunction (ED) and rheumatoid arthritis (RA) are associated with increased cardiovascular risk. It is unknown if these diagnoses are associated or if their combination confers additional cardiovascular risk. We aim to define the incidence of ED in RA, and determine if ED correlates with increased cardiovascular risk in RA.

METHODS: Medical information concerning RA, ED and cardiovascular diagnoses for men with RA (n=260) diagnosed in Olmsted county, Minnesota and age-matched male comparators was extracted from a comprehensive medical record system.

RESULTS: ED incidence was similar between the RA cohort and comparators (HR 0.80; 95% CI 0.55-1.16). In men with RA, ED diagnosis was associated with a trend toward an increase in peripheral arterial disease (HR 2.22; 95% CI 0.98-5.03) and a significantly decreased rate of myocardial infarction (HR 0.26; 95% CI 0.07-0.90), heart failure (HR 0.49; 95% CI 0.25-0.94) and death (HR 0.56; 95% CI 0.36-0.87). In men with RA and ED, phosphodiesterase-5 inhibitor use was associated with a decreased risk of death (HR 0.35; 95% CI 0.16-0.79), with a trending decreased risk of some cardiovascular diagnoses.

CONCLUSION: Incidence of ED was not statistically increased in RA. Although patients with both RA and ED had a similar overall cardiovascular risk to those with RA alone, men with both RA and ED had decreased risk of heart failure, myocardial infarction and death, as well as an increased risk of peripheral arterial disease. Further studies are needed to clarify these associations and their implications for pathogenesis and therapeutics.

PMID:33452166 | DOI:10.3899/jrheum.201226

Read the original post:
Erectile Dysfunction and Cardiovascular Risk in Men with Rheumatoid Arthritis: A Population- Based Cohort Study - DocWire News

Two arthritis drugs, tocilizumab and sarilumab, have re-emerged as possible treatment options for Covid-19 with the UK government recommending their use based on a new study. The use of arthritis drugs, especially tocilizumab, against coronavirus has been the subject of debate through the pandemic, emerging as a choice at times and falling out of favour at other times. The latest study, which is on a preprint server (which means that it is yet to be peer-reviewed), its results unlike those of previous trials suggest that tocilizumab and sarilumab could help save lives among Covid-19 patients admitted to an intensive care unit (ICU).

The study

Last week, the portal MedRxiv published results of the REMAP-CAP trial, which assessed 803 Covid-19 patients in ICU. Of them, 353 were administered tocilizumab within 24 hours of ICU admission, another 48 were given sarilumab within the same time-frame, and the remaining 402 were administered standard care minus these two drugs (the control arm).

While 64.2% ICU patients survived in the control arm, 72% survived when administered tocilizumab and 77.8% survived when given sarilumab.

The researchers found that the two arthritis drugs, now repurposed for Covid treatment, also helped reduce the need for organ support. Those given tocilizumab required organ support after 10 days on an average, those on sarilumab required after 11 days, and those in the control arm required organ support system in a single day.

What this could mean

This trial shows the drugs cannot be written off so easily, said Dr Shashank R Joshi, who has been part of another study to assess arthritis drug itolizumabs role in Covid-19 treatment. Joshi said despite multiple trial studies yielding unfavourable conclusions for immunosuppressants use against Covid-19, they have found tocilizumab (marketed as Actemra by Roche) effective if used at the correct time. In clinical practice we have observed that if a patient is on high flow nasal cannula and put on steroids, and if his condition deteriorates within next 24 hours in ICU, an immunosuppressant drug can be the correct intervention at that point. We have seen several patients turn around towards recovery, Joshi said.

In India, three immunosuppressant drugs tocilizumab, sarilumab, and itolizumab are used to treat rheumatoid arthritis. These drugs work against a protein called IL-6, which plays a key role in the body mounting a cytokine response (when the immune system attacks the bodys own cells) after the virus infects the body. By suppressing IL-6, these repurposed drugs are supposed to stop the self-damaging cytokine response in severe Covid-19 infections.

Red flags

The Indian Council of Medical Research has previously warned against indiscriminate use of drugs such as remdesivir and tocilizumab in Covid-19 patients as they can do more harm than good. Four months before the UK approved use of the arthritis drugs, Maharashtra had removed tocilizumab from its Covid-19 treatment protocol. Several trials and studies had led to this decision. The most crucial one came from tocilizumab manufacturer Roche in July 2020: it published phase-III trial results that found tocilizumab did not meet the primary endpoint of clinical improvement or the secondary endpoint of reduction in mortality.

In October 2020, the New England Journal of Medicine published a study on 243 patients that found tocilizumab was not effective in preventing death in moderately ill, hospitalised Covid-19 patients.

In September 2020, pharma giant Sanofi halted its trial on sarilumab stating it did not work against Covid-19 after testing it on 420 patients. That July, Sanofi had halted a similar trial in the US after assessing 194 patients. In fact, Sanofi had said sarilumab was associated with a 3% higher risk of adverse events in comparison to the placebo group.

Unsettled debate

Why are the latest findings so contradictory? Intensivist Dr Rahul Pandit, who was himself treated with tocilizumab for Covid-19 last year, said he has completely stopped use of the drug. We cannot rush into a conclusion with this one new research. We need to look at bigger data, Pandit said.

Pandit stopped use of tocilizumab and itolizumab five months ago. There was no evidence of improvement or reduction in mortality. Patients are at risk of secondary infection with this drug, he said.

But as Dr Joshi puts it, Each clinical trial has a different yardstick to measure the endpoint. This is only a year-old illness. We need to wait for more data before writing off drugs.

See original here:
Now out of favour, now back: arthritis drugs in Covid-19 treatment - The Indian Express

About 374,000 Canadians live with rheumatoid arthritis which affects their joins and puts them at higher risk for other health problems. (ljubaphoto/iStock)

People who have been diagnosed with rheumatoid arthritis have an increased risk of cardiovascular disease and infection. Researchers at Arthritis Research Canada have found that they also have a higher risk of developing life threatening blood clots.

Rheumatoid arthritis (RA) occurs when the bodys immune system mistakenly attacks the lining of the joints and other tissues causing swelling, pain, and stiffness. It can affect almost all organ systems and cause such things as cardiovascular problems, infections, depression and gastrointestinal ulcers. About 1.2 per cent of Canadian aged 16 and older live with the condition. It affects more women than men.

For this study, the researchers investigated the risk of blood clots that start in a vein and can travel to the lungs and blood clots in veins of the leg. These kinds of clots (VTE) affect more than one in 1,000 people in Western populations each year.

Dr. Antonio Avia-Zubieta says the higher risk of blood clots must be taken into account in treating patients diagnosed with rheumatoid arthritis. (Sombilon Studios)

The study found that the risk of VTE was highest in the first year after patients are diagnosed with rheumatoid arthritis. The risk decreases progressively as patients are treated for the inflammation associated with arthritis but it is still significantly higher five years later.

These findings have important implications for clinical care, both immediately after a rheumatoid arthritis diagnosis and in long-term treatment as treating inflammation decreases the risk, said Antonio Avia-Zubieta, a rheumatologist and senior scientist of rheumatology at Arthritis Research Canada. Clinicians should be aware that RA causes patients to have a higher risk not only of heart attacks and strokes, but also VTE, particularly in the period soon after diagnosis.

The study was published in the journal Rheumatology.

Arthritis Research Canada is the largest clinical research institution in North America.

Read the original here:
Rheumatoid arthritis patients at higher risk of dangerous blood clots: study - Radio Canada International - English Section

The Global Rheumatoid Arthritis Treatment Market report provides a holistic evaluation of the market for the forecast period (20192025). The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market. These factors; the market dynamics involve the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Rheumatoid Arthritis Treatment Market study provides an outlook on the development of the market in terms of revenue throughout the prognosis period.

In order to present an executive-level model of the market and its future perspectives, the Rheumatoid Arthritis Treatment Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration of patient education, exercise, medications, and surgery (occasionally).

Major Players included in this report are as follows Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/166

Rheumatoid Arthritis Treatment Market: Regional analysis includes:

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Rheumatoid Arthritis Treatment Market.

Rheumatoid Arthritis Treatment Market scope

A basic summary of the competitive landscape A detailed breakdown of the regional expanse A short overview of the segmentation

Furthermore, this study will help our clients solve the following issues:

Cyclical dynamics We foresee dynamics of industries by using core analytical and unconventional market research approaches. Our clients use insights provided by us to maneuver themselves through market uncertainties and disruptions.

Identifying key cannibalizes Strong substitute of a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance.

Spotting emerging trends Our Ecosystem offering helps the client to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis helps clients to have an early mover advantage.

Interrelated opportunities This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in the real world.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/166

Some of the Major Highlights of TOC covers:

Rheumatoid Arthritis Treatment Regional Market Analysis

Rheumatoid Arthritis Treatment Production by Regions Global Rheumatoid Arthritis Treatment Production by Regions Global Rheumatoid Arthritis Treatment Revenue by Regions Rheumatoid Arthritis Treatment Consumption by Regions

Rheumatoid Arthritis Treatment Segment Market Analysis (by Type)

Global Rheumatoid Arthritis Treatment Production by Type Global Rheumatoid Arthritis Treatment Revenue by Type Rheumatoid Arthritis Treatment Price by Type

Rheumatoid Arthritis Treatment Segment Market Analysis (by Application)

Global Rheumatoid Arthritis Treatment Consumption by Application Global Rheumatoid Arthritis Treatment Consumption Market Share by Application (2014-2019)

Rheumatoid Arthritis Treatment Major Manufacturers Analysis

Rheumatoid Arthritis Treatment Production Sites and Area Served Product Introduction, Application and Specification Rheumatoid Arthritis Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)Main Business and Markets Served

Key questions answered in the report:

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/166

Key Benefits

Major countries in each region are mapped according to individual market revenue. Comprehensive analysis of factors that drive and restrict market growth is provided. The report includes an in-depth analysis of current research and clinical developments within the market. Key players and their key developments in recent years are listed.And More.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com

Excerpt from:
Rheumatoid Arthritis Treatment Market With Focus On Growth Analysis, Production, Consumption, Revenue, Analysis By 2026 | Pfizer, Inc., Johnson &...

Rheumatoid arthritis and pregnancy: Heres what women with RA need to know  |  Photo Credit: iStock Images

New Delhi: Pregnancy is a beautiful phase in a womans life. But what if you have a condition like rheumatoid arthritis (RA), you may have a number of questions, including how it will affect your pregnancy and the babys development. And theres another vital question - will I be able to care for my new baby.

If you have rheumatoid arthritis and are pregnant or planning to become pregnant, its important to know how RA and pregnancy can affect each other. Rheumatoid arthritis is a chronic inflammatory disorder that affects many joints, including those in the hands and feet. It may strike women in their mid-twenties and early 30s, aprimary time period when a woman plans her pregnancy. In this article, Dr Singhai Shweta, consultant - rheumatology- Sakra World Hospital, Bengaluru, tells us how rheumatoid arthritis could affect pregnancy and what women can do to manage their condition, which will enable them a healthy pregnancy and a healthy baby.

It has been observed that most pregnant women with RA have low disease activity during pregnancy and may get remission by the third trimester. However, among few women with severe disease activity, the condition can lead to several complications like preterm birth, raised blood pressure or preeclampsia, low birth weight babies and increased possibility of C-section delivery. Thus, those with controlled RA certainly have healthier pregnancies and babies than those with worse disease activity.

Rheumatoid arthritis may cause low birth weight babies. Also, about 3 per cent to 5 per cent of newborns to mothers with acute RA may have birth defects. This happens due to certain antirheumatic drugs that may mess up with the foetal formation. This is why a woman with RA must essentially consult a doctor before planning a pregnancy.

Things a pregnant mom with RA must keep in mind:

A majority of pregnant women, as much as 60 per cent, experience improvement in their symptoms due to a number of reasons, such as:

Managing rheumatoid arthritis is extremely essential for a healthy pregnancy and a healthy baby. Heres what women can do to manage RA effectively:

Also, stay away from foods that may cause a flare-up: Identify the foods that may worsen the condition and avoid them to prevent a flare-up.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read this article:
Rheumatoid arthritis and pregnancy: Heres what women with RA need to know - Times Now

Getting dressed, brushing teeth, opening a jar to make a meal: many Canadians can take performing these tasks for granted. But for those living with osteoarthritis in their hands, the gripping and twisting motions of daily life are a regular source of pain and frustration.

It can affect everything. Living with pain certainly has an impact, but it extends to all dimensions of life, said Joy MacDermid, professor of physical therapy and co-director of the clinical research lab at the Roth | McFarlane Hand and Upper Limb Centre.

There are also economic implications if work is affected, as well as increased risk for isolation and depression. We often hear from people whove had to give up things they value, like participating in sports, or doing crafts they used to enjoy, said MacDermid. Those activities are related to their social life and often done with friends.

Joy MacDermid, PhD

She and her colleagues are working on improving the quality of life for those living with hand osteoarthritis by studying the force used in daily tasks to develop new joint protection programs. Her research, done with the assistance of Pavlos Bobos, PhD20, and in collaboration with engineering professors Louis Ferreira and Emily Lalone through Westerns Bone and Joint Institute, has received recognition from the Arthritis Society as one of its Top 10 Research Advances of 2020.

Pavlos Bobos, PhD

Louis Ferreira, PhD

Emily Lalone, PhD

Joint protection programs a group of strategies to decrease strain on the joints have included training patients to do tasks differently, to use assistive devices or to pace high-force activities like carrying a heavy laundry basket throughout the day.

Until now, these programs have been based on theory alone, MacDermid said. Weve always thought if you put your joint in a neutral position, it makes sense biomechanically that it would lessen force through the joints, but we didnt have measurements demonstrating that joint protection worked. We needed devices to do that.

Thats where Ferreiras and Lalones expertise in mechanical and material engineering, and specifically wearable technology, comes in. Ferreira designed a sensor allowing Lalone and her graduate students to measure, in real time, the forces in fingertips when performing functional tasks. Tiny strain gauges attached to the nailbed pick up a recording when the finger is depressed.

Sensors embedded in finger sleeves measured the force of daily tasks.

The first design saw the sensor embedded in fake fingernails, then evolved through the teams investigations to be worn in small finger sleeves by test subjects in MacDermids lab.

We had a kitchen area set up and a series of standardized tasks that patients would go through, such as pouring a tea kettle or lifting a cup, she said. Patients were tested, first doing tasks their own way, then repeating them using joint protection strategies. The subjects were videotaped, and data on the amount of movement and force used for each task was analyzed.

Early results showed some strategies are very effective in reducing the amount of force going through the joint, but there were also unexpected observations. There seems to be some tasks that people naturally gravitate toward doing correctly, MacDermid said. For example, patients knew inherently how to lift a kettle in the best way to avoid strain. But with other tasks they had no idea when they were doing it incorrectly.

Biofeedback, in the form of an audio or visual cue while doing a task, could help patients avoid joint strain in the future, the study found.

This is part of MacDermids long-term vision, made possible through the transdisciplinary effort fostered through the Bone and Joint Institute.

We first want to create an intervention where people would wear the sensors in the clinic and get feedback, she said. But in the long-term, as sensor technology develops and becomes more stable, were hoping we can give people a kit that gives them feedback when they practise the tasks in their own home for two or three weeks.

Shes hoping her work will also influence updates to patient training materials, noting some still suggest using a pencil rather than a finger to dial a rotary phone. The tasks people do today and the types of assistive devices we have to help people now are so different.

The rest is here:
Combined forces help combat the pain and disability of arthritis - Western News

Background:The effect of mannose-binding lectin (MBL) gene polymorphisms on susceptibility of rheumatoid arthritis (RA) were evaluated in ethnically different populations, whereas the results were always inconsistent.

Materials and methods:Fourteen articles involving 36 datasets were recruited to evaluate the association between MBL gene polymorphisms and rheumatoid arthritis in a meta-analysis. The random or fixed effect models were used to evaluate the pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).

Results:Stratified analysis by ethnicities was conducted and the result revealed that rs1800450 (T vs C, OR = 1.32, 95% CI: 1.04-1.67, P < .05) and MBL-A/O (T vs C, OR = 1.20, 95% CI: 1.08-1.34, P < .001) were strongly associated with RA in Brazilian populations. In addition, the significant relationship between rs11003125 (T vs C, OR = 1.16, 95% CI: 1.06-1.26, P < .05) with RA were also observed in East Asian populations. Meanwhile, the inverse associations between rs5030737 with RA in East Asians and rs1800450 with RA in Indians were acquired. However, no association between any MBL polymorphism with RA susceptibility was confirmed in Caucasians.

Conclusions:The structural polymorphisms in exon 1 of MBL gene may significantly contribute to susceptibility and development of RA in Brazilian and Indian populations, whereas the functional polymorphisms in the promoter region were more likely to associate with RA in East Asians.

Keywords:mannose-binding lectin; meta-analysis; polymorphism; rheumatoid arthritis.

Go here to see the original:
Effect of mannose-binding lectin gene polymorphisms on the risk of rheumatoid arthritis: Evidence from a meta-analysis - DocWire News

Objectives: To investigate whether low social support or low decision latitude at work correlate with risk of rheumatoid arthritis (RA), and whether and how those factors are associated with known modifiable risk factors for RA.

Method: The Swedish population-based EIRA study included, from 1996 to 2015, 3724 incident RA cases and 5935 controls, matched for age, gender, and residential area. Participants filled in detailed questionnaires at diagnosis. Using logistic regression, we investigated whether low social support and low decision latitude at work were associated with RA risk, and whether and how these exposures are associated with known modifiable risk factors for RA.

Results: Low decision latitude at work was associated with RA risk in unadjusted analyses [odd ratio (OR) = 1.52, 95% confidence interval (CI) = 1.20-1.94], but this association was weakened after adjustment for known RA risk factors (adjusted OR = 1.24, 95% CI = 0.93-1.63). Low social support was not associated with RA risk (unadjusted OR = 1.05, 95% CI = 0.95-1.15). Cases reporting low decision latitude were more often smokers (OR = 2.05, 95% CI = 1.33-3.16), without university degrees (OR = 8.23, 95% CI = 5.13-13.22), and more often female (OR = 2.52, 95% CI = 1.66-3.81), with a similar pattern among controls. Cases reporting low social support were more often men (OR = 1.60, 95% CI = 1.40-1.83), smokers (OR = 1.46, 95% CI = 1.26-1.70), obese (OR = 1.29, 95% CI = 1.09-1.54), physically inactive (OR = 2.78, 95% CI = 1.98-3.90), and without university degrees (OR = 2.04, 95% CI = 1.77-2.36), with a similar pattern among controls.

Conclusion: Low decision latitude coexisted with several known environmental/social risk factors for RA, together defining groups of individuals at increased risk of RA. These risk factors should be viewed in context when testing actions to diminish RA risk in prospective studies.

Visit link:
Social stressors and risk of rheumatoid arthritis and their relationship to known modifiable risk factors: results from the Swedish EIRA study -...

Objective:RA is associated with higher risk of cardiovascular (CV) disease. Ongoing systemic inflammation is presumed to accelerate atherosclerosis by increasing inflammation in the arterial wall. However, evidence supporting this hypothesis is limited. We aimed to investigate arterial wall inflammation in RA vs OA, and its association with markers of inflammation and CV risk factors.

Methods:18-fluorodeoxyglucose PET combined with CT (18F-FDG-PET/CT) was performed in RA (n = 61) and OA (n = 28) to investigate inflammatory activity in the wall of large arteries. Secondary analyses were performed in patients with early untreated RA (n = 30), and established RA, active under DMARD treatment (n = 31) vs OA.

Results:Patients with RA had significantly higher 18F-FDG uptake in the wall of the carotid arteries (beta 0.27, 95%CI 0.11-0.44, P <0.01) and the aorta (beta 0.47, 95%CI 0.17-0.76, P <0.01) when compared with OA, which persisted after adjustment for traditional CV risk factors. Patients with early RA had the highest 18F-FDG uptake, followed by patients with established RA and OA respectively. Higher ESR and DAS of 28 joints values were associated with higher 18F-FDG uptake in all arterial segments.

Conclusion:Patients with RA have increased 18F-FDG uptake in the arterial wall compared with patients with OA, as a possible marker of early atherosclerosis. Furthermore, a higher level of clinical disease activity and circulating inflammatory markers was associated with higher arterial 18F-FDG uptake, which may support a role of arterial wall inflammation in the pathogenesis of vascular complications in patients with RA.

Keywords:FDG PET/CT; RA; atherosclerosis; inflammation.

Read the rest here:
Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis - DocWire News

VERSUS Arthritis, the UKs leading charity for people with arthritis, has appointed Dr Neha Issar-Brown as its new Director of Research.

Neha joins from Fight for Sight where she was Director of Research, Policy and Innovation, supporting pioneering research to prevent sight loss. She also initiated the framework for the charitys first patient-centred research strategy.

In her new role, Neha will be responsible for developing Versus Arthritis own research strategy, aimed at making sure that research discoveries are rapidly translated into life-changing treatments for people with arthritis, along with ensuring that the level of investment in arthritis research reflects the prevalence of a condition that impacts one in six people in the UK.

Her previous roles include Head of Population Health and System Medicine at the UKRIs Medical Research Council (MRC).

Neha will be taking up her new position in February and said:

I am thrilled to be joining Versus Arthritis at this exciting time in the development of its research strategy.

I am particularly excited about working for an organisation that has such a strong track record in putting people with arthritis at the heart of its work, ensuring that no decision is made without the involvement of those who will be directly impacted.

Im looking forward to becoming part of an amazing team and to driving progress for millions of people with arthritis.

Ellen Miller, Deputy Chief Executive of Versus Arthritis, said:

Were delighted to welcome Neha to Versus Arthritis at such a significant time.

The COVID-19 pandemic and Brexit have put a huge strain on medical research charities, but with Nehas breadth of experience alongside our incredible partners and supporters, were in a very good position to build on and continue supporting world-leading research that will fundamentally change the lives of people with arthritis.

See the article here:
Versus Arthritis appoints new director of research - Charity Today News

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Global revenues from RA drug sales are expected to grow from $26.2B in 2019 to $29.1B in 2029.

The publisher projects that the global RA marketplace - which, for the purposes of this report, comprises eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia) - will grow at a compound annual growth rate (CAGR) of 1.0% over the 10-year forecast.

Global growth in the RA market will be driven by continued uptake of new products in the IL-6 and JAK inhibitor classes along with the anticipated approval and launch of four pipeline therapies. This growth will be slackened by sales erosion from biosimilars and generic tofacitinib. Over 70% of sales will come from the US; the US has a large population of RA patients (estimated 1.8M diagnosed prevalent cases in 2029) and high price tags for biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs).

Biosimilar erosion will temper the growth of the RA market during the forecast period; between 2019 and 2029, biosimilars sales will increase from 5% to 28% of global sales. Due to favorable local regulations and increased access, biosimilar uptake is expected to be the highest in the 5EU; by 2029, the publisher projects that biosimilar sales in 5EU will represent over 45% of its total sales -60% of which will come from sales of adalimumab and etanercept biosimilars.

The publisher expects that despite biosimilar erosion, Pfizer/Amgen's Enbrel and AbbVie's Humira will remain the global sales leaders during the forecast period, amassing combined sales of $12.6B in 2019 and $9.0B in 2029. Sales of Enbrel and Humira are more likely to be protected from biosimilar erosion than Remicade (negative CAGR of 6.8%) mainly due to a lack of biosimilar availability in the US, the largest RA market in the 8MM. Etanercept and adalimumab biosimilars will not be available in the US until 2028 and 2023, respectively.

Although biosimilars may temper the impact of blockbuster biologics, the publisher expects that the growth of the small molecule Janus kinase (JAK) inhibitor class will powerfully shape the RA market of the future. The publisher projects that the JAK inhibitor class will continue to grow significantly over the forecast period, increasing at a CAGR of 7.2%. This growth is expected to be strongest in the 5EU, where the first JAK inhibitors, Pfizer's Xeljanz and Eli Lilly's Olumiant, only became available starting in 2017. The recent global launch of AbbVie's JAK1 inhibitor, Rinvoq, is expected to significantly expand JAK inhibitor market share, bringing in $2.2B in sales by 2029.

The late-stage pipeline for RA consists of three subcutaneously delivered biologics (the TNF inhibitor ozoralizumab, the interleukin 6 [IL-6] inhibitor olokizumab, and the granulocyte-macrophage colony-stimulating factor [GM-CSF] inhibitor otilimab) and one oral kinase inhibitor (the BTK inhibitor fenebrutinib). Key opinion leaders (KOLs) expressed measured enthusiasm for these agents-they welcomed the potential availability of new mechanisms of action but did not think that any of them would be more or even equally effective as JAK inhibitors.

Of these agents, KOLs were the most enthusiastic about GSK's GM-CSF inhibitor, otilimab, expected to achieve global sales of $626.8M by 2029. All together, these four pipeline agents are expected to claim less than 5% of the RA market in 2029, equivalent to about $1.1B.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

2.1 Biosimilar and Generic Erosion Will Stymie Sales Growth in the RA Market from 2019-2029

2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies

2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA Patients

2.4 Late-Stage RA Pipeline Holds Promise But Likely Won't Match the Utility of JAK Inhibitors

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.2 Pathophysiology

4.3 Symptoms and Severity Classifications

5 Epidemiology

5.1 Risk Factors and Comorbidities

5.2 Global and Historical Trends

5.3 Forecast Methodology

5.4 Epidemiological Forecast for RA (2019-2029)

5.5 Discussion

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

6.5 Australia

7 Competitive Assessment

7.1 Overview

7.2 Biosimilars in the RA Market

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Earlier Diagnosis and Treatment

8.3 Cost-Effective Therapies

8.4 Personalized Treatment Strategies

8.5 Improved Guidance on Treating RA Patients in Remission

8.6 New Treatment Options for Patients with Refractory RA

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Other Drugs in Development - Kinase Inhibitors

10. Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Portfolio Assessments

11. Market Outlook

11.1 Global Markets

11.2 US

11.3 5EU

11.4 Japan

11.5 Australia

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ba8mff

Read the original here:
Global Rheumatoid Arthritis (RA) Market Analysis & Drug Forecasts, 2019-2020 & 2029 - Biosimilar and Generic Erosion Will Stymie Sales Growth...

Mary Berry, 85, is very hands on when it comes to baking, with numerous cooking shows and books behind her that fans wonder if there's anything those hands of hers can't do! But the pastry whizz admitted she suffers with a "funny left hand"; the aftermath of suffering with polio when she was younger.

Polio is a serious viral infection that used to be common in the UK and worldwide, which can infect a person's spinal cord, causing paralysis of the limbs.

At the age of 13, Marycontracted the disease and spent three months in hospital in isolation.

The condition only affected the left side of her body, affecting her hand which isoften mistaken forarthritisby television viewers.

Regardless, she admitted she was "let off very lightly" under the circumstances.

READ MORE:Bake Off star Dave Friday's fiance diagnosed with sepsis

In a recent interview, the 85-year-old spoke about her diagnosis and how she would urge everyone to take the vaccine to protect themselves against the relentless disease.

"I had polio, but now almost the whole world is vaccinated against it," she said.

"If youre in a hospital like I was, with people in callipers, people in pain, people who werent going to get better I think everyone should take the vaccine, not query it, and think of others."

She added: "I was immensely fortunate. I only had it on my left side, and Ive got a funny left hand.

"Everybody thinks Ive got arthritis. I look a bit funny when Im rolling pastry, but I have no other difficulties whatsoever."

She confessed she wasn't as good as sport as she used to be prior to the illness but remains "grateful".

"I was let off very lightly. Im grateful," she told Radio Times.

Her previous health battle comes after Mary and her husband both received the coronavirus vaccine earlier this month, as the UK government continue to roll the Pfizer vaccine, which has currently reached over four million people.

Much like her appreciation for vaccines for viral diseases such as polio, Mary was adamant no one should turn this down.

DON'T MISS...Ralf Little embroiled in row with Death In Paradise director on-setHomes Under The Hammer's Martin Roberts attacks 2020 sign with hammerCountdown's Susie Dent tried to persuade Joe Lycett to 'get willy out'

She said: "I was so pleased, particularly for my husband.

"I would encourage everyone, if its offered to them, to definitely have the vaccine."

Like the rest if us, she has been separated from her family members for far too long, unable to see much of her five grandchildren during lockdown but she explained they have kept in touch by phone.

"I think that were very lucky in this day and age to have all these different forms of communication," Mary admitted.

She continued to joke: "And because Im quite ancient, Ive got a lot of girlfriends whove lost their husbands or their other halves. Its been great having phone calls with them. What are they getting up to? How are they coping?"

She explained she makes sure she rings someone every day to have a "long, long chat", something she never would have found the time to do before.

Mary's full interview is available to read now in Radio Times.

Link:
Mary Berry explains 'funny' left hand and health battle: 'Everybody thinks it's arthritis' - Express

Objectives:To quantify the prevalence of co-morbidities in patients with early RA and determine their prognostic value for effectiveness outcomes in a randomized trial.

Methods:We included patients from the 2-year pragmatic randomized CareRA trial, who had early RA (diagnosis < 1 year), were DMARD nave and then treated-to-target with different remission induction schemes. Prevalence of co-morbidities was registered at baseline and the Rheumatic Diseases Comorbidity Index (RDCI; range 0-9) was calculated. We tested the relation between baseline RDCI and outcomes including disease activity (DAS28-CRP), physical function (HAQ index), quality of life (SF-36 domains) and hospitalizations over 2 years, using linear mixed models or generalized estimating equations models.

Results:Of 379 included patients, 167 (44%) had a RDCI of minimum 1. RDCI scores of 1, 2 or 3 were obtained in 65 (17%), 70 (19%), and 32 (8%) participants, respectively. The most frequent co-morbidity was hypertension (22%). Patients with co-morbidities had significantly higher HAQ ( = 0.215; 95% CI: 0.071, 0.358), DAS28-CRP ( = 0.225; 95% CI: 0.132, 0.319) and lower SF-36 physical component summary scores ( =-3.195; 95% CI: -4.844, -1.546) over 2 years than patients without co-morbidities, after adjusting for possible confounders including disease activity and randomized treatment. Patients with co-morbidities had over time lower chances of achieving remission (OR = 0.724; 95% CI: 0.604, 0.867) and a higher risk of hospitalization (OR = 3.725; 95% CI: 2.136, 6.494).

Conclusion:At disease onset, almost half of RA patients had at least one clinically important co-morbidity. Having co-morbidities was associated with worse functionality and disease activity outcomes over 2 years, despite intensive remission induction treatment.

Trial registration:Clinical trialsNCT01172639.

Keywords:co-morbidities; csDMARDs; disease activity; functionality; glucocorticoids; rheumatoid arthritis; treatment strategies.

See original here:
Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic...

A man living in permanent pain and left virtually housebound by arthritis who had his hip operation cancelled due to the pandemic has said he cannot see how the mounting NHS waiting list backlog will be sorted.

Chris Bulteel was diagnosed with arthritis in his right hip in 2018 and was due to have a hip replacement in March 2020 but the operation was cancelled due to the coronavirus outbreak.

He told the PA news agency that although he had been told he would be top of the list for another operation he said he was later taken off the waiting list and does not know when he will receive the vital surgery.

The 71-year-old from Dorset added: While I have got a supportive family who make my life a lot easier I couldnt cope on my own I worry about all those people who are on their own.

They must be really suffering, its a terrible situation and I cant see how they ever get this waiting list back to normal.

I am in permanent pain, its quite severe at times.

Its there all the time in the background. I have to have a chair that lifts me up in the air, it really is a struggle to get around on two crutches.

Its getting gradually worse and I can see a time coming up when I wont be able to walk at all.

Mr Bulteel, who said he is supported by his wife Angela and his daughter Sarah and her partner, said that he understood the need to cancel surgery due to the pandemic.

But he said he just wanted to know when he could have the operation.

The former care worker added: I appreciate they are not doing anything at the moment because of the pandemic but it would be nice to know what the situation is because of the waiting lists.

I used to be on the top but now Im not on it at all.

Mr Bulteel said he has only left his flat twice since March for hospital appointments, cannot shower unaided or get down the steps to his garden and is on medication for the pain.

He also said he worries he will not be able to get the coronavirus vaccine because he wont be able to get to a vaccination centre.

Mr Bulteel added: I havent been out since March, except for two visits to the hospital.

I am lucky I live in a ground floor flat and have a garden to look out into but I cant even get out because theres a step I cant negotiate.

Im also worried I cant have the vaccine when the time comes because I cant get to any vaccination centre.

Mr Bulteel said he had taken up writing but he now cannot sit at his computer for more than 10 minutes.

He said that after the operation he wants to write again as well as hopefully go back and do some care work again.

He said the operation would mean an awful lot to him and his family and added: I know Im not a burden but you feel you are.

Tracey Loftis, head of policy and public affairs at the charity Versus Arthritis said delays to treatment can lead to serious physical and mental health implications.

She added: Delays to planned treatment can lead to serious physical and mental health implications, especially for those with arthritis who have debilitating pain or limited mobility.

Whilst it is understandable that operations are cancelled at this time, thousands of people are having to endure longer periods of pain.

People waiting for joint replacement surgery urgently need clear communication about their care, and support including advice on pain management and mental health and wellbeing.

Read more:
Arthritis patient cannot see how surgery waiting lists will be fixed - Aberdeen Evening Express

Fort Collins, Colorado: Reports Globe has published the latest study on Prescription Arthritis Medications Market Report Analysis by Size with Future Outlook, Key Players SWOT Analysis and Forecast to 2026. It uses exploratory techniques such as qualitative and quantitative analysis to identify and present data on the target market. Successful sales strategies have been mentioned that will help you do business in record time and multiply customers.

This report is presented clearly and concisely to help you better understand the structure and dynamics of the market. The trends and recent developments in the Prescription Arthritis Medications market were analyzed. The opportunities that lead to the growth of the market were analyzed and presented. Focusing on the global market, the report provides answers to the key questions stakeholders are facing today around the world. Information on market size raises the problem of increasing competitiveness and hampering market-leading sectors and market growth.

Get Exclusive Sample of Report on Prescription Arthritis Medications market is available @ https://reportsglobe.com/download-sample/?rid=113490

Some of the Important and Key Players of the Global Prescription Arthritis Medications Market:

Prescription Arthritis Medications market research report provides detailed information on the following aspects: Industry Size, Market Share, Growth, Segmentation, Manufacturers and Advancement, Key Trends, Market Drivers, Challenges, Standardization, Deployment Models, Opportunities, Strategies, Future Roadmaps and Annual Forecasts to 2027, etc. The report will help you also in understanding the dynamic structure of the Prescription Arthritis Medications market by identifying and analyzing market segments. The Global Prescription Arthritis Medications 2021 Industry Research Report has given the expected compound annual growth rate (CAGR) as a% of value for a given period of time and clearly helps the user make their decision based on the futuristic chart of the key players on the global Prescription Arthritis Medications market. The report introduces some of the major players in the global Prescription Arthritis Medications market and offers insightful information about the Prescription Arthritis Medications industry such as Business Overview, Prescription Arthritis Medications Market Product Segmentation, Revenue Segmentation, and the Latest Information. Developments.

Additionally, the Prescription Arthritis Medications market report includes a comprehensive strategic review as well as summarized studies of the growth, key factors, and market opportunity by which to evaluate the Prescription Arthritis Medications market and other important market related details on Prescription Arthritis Medications. The investigation of the research report also helps uncover accurate industry statistics depicting the ultimate model of the global Prescription Arthritis Medications market, including various types, applications, market growth structures, and opportunities. In addition, the study of the market research report provides an investigation and analysis of the past and current performance of the regional market that includes regions by department and subdivision. This regional analysis studies various key market parameters such as Prescription Arthritis Medications market growth rate in each region, production volume and capacity, market demand and supply, and return on investment (RoI).

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=113490

Some of the key questions answered in the report include-

1. What is the overall structure of the market?2. What was the historical value and what is the forecasted value of the market?3. What are the key product level trends in the market?4. What are the market level trends in the market?5. Which of the market players are leading and what are their key differential strategies to retain their stronghold?6. Which are the most lucrative regions in the market space?

Browse the complete report @ https://reportsglobe.com/product/global-prescription-arthritis-medications-market-insight-and-forecast/

Global Prescription Arthritis Medications market is segmented based by type, application and region.

Prescription Arthritis Medications Market Segmentation, By Type

Prescription Arthritis Medications Market Segmentation, By Application

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Global Prescription Arthritis Medicationsmarket Key Report Highlights:

This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary, and market segments The report also includes sections on the competitive spectrum, highlighting major players, with a detailed assessment of supply chain management, competition dynamics, and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis, and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in the global Prescription Arthritis Medications market.A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post-COVID-19 market environment.

Major Points from Table of Content:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Prescription Arthritis Medications Market Overview5. Prescription Arthritis Medications Supply Chain Analysis6. Prescription Arthritis Medications Pricing Analysis7. Global Prescription Arthritis Medications Market Analysis and Forecast by Type8. Global Prescription Arthritis Medications Market Analysis and Forecast by Application9. Global Prescription Arthritis Medications Market Analysis and Forecast by Sales Channel10. Global Prescription Arthritis Medications Market Analysis and Forecast by Region11. North America Prescription Arthritis Medications Market Analysis and Forecast12. Latin America Prescription Arthritis Medications Market Analysis and Forecast13. Europe Prescription Arthritis Medications Market Analysis and Forecast14. Asia Pacific Prescription Arthritis Medications Market Analysis and Forecast15. Middle East & Africa Prescription Arthritis Medications Market Analysis and Forecast16. Competition Landscape

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://reportsglobe.com/need-customization/?rid=113490

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Originally posted here:
Prescription Arthritis Medications Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 - NeighborWebSJ

Fort Collins, Colorado: Reports Globe has published the latest study on Seropositive Rheumatoid Arthritis Drug Market Report Analysis by Size with Future Outlook, Key Players SWOT Analysis and Forecast to 2026. It uses exploratory techniques such as qualitative and quantitative analysis to identify and present data on the target market. Successful sales strategies have been mentioned that will help you do business in record time and multiply customers.

This report is presented clearly and concisely to help you better understand the structure and dynamics of the market. The trends and recent developments in the Seropositive Rheumatoid Arthritis Drug market were analyzed. The opportunities that lead to the growth of the market were analyzed and presented. Focusing on the global market, the report provides answers to the key questions stakeholders are facing today around the world. Information on market size raises the problem of increasing competitiveness and hampering market-leading sectors and market growth.

Get Exclusive Sample of Report on Seropositive Rheumatoid Arthritis Drug market is available @ https://reportsglobe.com/download-sample/?rid=107660

Some of the Important and Key Players of the Global Seropositive Rheumatoid Arthritis Drug Market:

Seropositive Rheumatoid Arthritis Drug market research report provides detailed information on the following aspects: Industry Size, Market Share, Growth, Segmentation, Manufacturers and Advancement, Key Trends, Market Drivers, Challenges, Standardization, Deployment Models, Opportunities, Strategies, Future Roadmaps and Annual Forecasts to 2027, etc. The report will help you also in understanding the dynamic structure of the Seropositive Rheumatoid Arthritis Drug market by identifying and analyzing market segments. The Global Seropositive Rheumatoid Arthritis Drug 2021 Industry Research Report has given the expected compound annual growth rate (CAGR) as a% of value for a given period of time and clearly helps the user make their decision based on the futuristic chart of the key players on the global Seropositive Rheumatoid Arthritis Drug market. The report introduces some of the major players in the global Seropositive Rheumatoid Arthritis Drug market and offers insightful information about the Seropositive Rheumatoid Arthritis Drug industry such as Business Overview, Seropositive Rheumatoid Arthritis Drug Market Product Segmentation, Revenue Segmentation, and the Latest Information. Developments.

Additionally, the Seropositive Rheumatoid Arthritis Drug market report includes a comprehensive strategic review as well as summarized studies of the growth, key factors, and market opportunity by which to evaluate the Seropositive Rheumatoid Arthritis Drug market and other important market related details on Seropositive Rheumatoid Arthritis Drug. The investigation of the research report also helps uncover accurate industry statistics depicting the ultimate model of the global Seropositive Rheumatoid Arthritis Drug market, including various types, applications, market growth structures, and opportunities. In addition, the study of the market research report provides an investigation and analysis of the past and current performance of the regional market that includes regions by department and subdivision. This regional analysis studies various key market parameters such as Seropositive Rheumatoid Arthritis Drug market growth rate in each region, production volume and capacity, market demand and supply, and return on investment (RoI).

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=107660

Some of the key questions answered in the report include-

1. What is the overall structure of the market?2. What was the historical value and what is the forecasted value of the market?3. What are the key product level trends in the market?4. What are the market level trends in the market?5. Which of the market players are leading and what are their key differential strategies to retain their stronghold?6. Which are the most lucrative regions in the market space?

Browse the complete report @ https://reportsglobe.com/product/global-seropositive-rheumatoid-arthritis-drug-market-insight-and-forecast/

Global Seropositive Rheumatoid Arthritis Drug market is segmented based by type, application and region.

Seropositive Rheumatoid Arthritis Drug Market Segmentation, By Type

Seropositive Rheumatoid Arthritis Drug Market Segmentation, By Application

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Global Seropositive Rheumatoid Arthritis Drugmarket Key Report Highlights:

This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary, and market segments The report also includes sections on the competitive spectrum, highlighting major players, with a detailed assessment of supply chain management, competition dynamics, and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis, and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in the global Seropositive Rheumatoid Arthritis Drug market.A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post-COVID-19 market environment.

Major Points from Table of Content:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Seropositive Rheumatoid Arthritis Drug Market Overview5. Seropositive Rheumatoid Arthritis Drug Supply Chain Analysis6. Seropositive Rheumatoid Arthritis Drug Pricing Analysis7. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Type8. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Application9. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Sales Channel10. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Region11. North America Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast12. Latin America Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast13. Europe Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast14. Asia Pacific Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast15. Middle East & Africa Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast16. Competition Landscape

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://reportsglobe.com/need-customization/?rid=107660

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Visit link:
Seropositive Rheumatoid Arthritis Drug Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 - NeighborWebSJ